SPEECH-PROCESSING
18.11.2015 10:09:46 CET | Business Wire | Press release
Speech Processing Solutions , the worldwide leader in professional dictation has received excellent reviews for its Philips SpeechMike Premium. The proven and almost indestructible dictation microphone offers users superior audio quality, coupled with unique antimicrobial housing and excellent ergonomics. The fully customizable dictation microphone saves time, increases efficiency and ultimately lowers costs for professionals across a variety of industry sectors.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151118005582/en/
The leader in healthcare
Philips SpeechMike has become a household name in many industries, particularly in the healthcare sector where the dictation microphone seamlessly integrates into leading healthcare IT systems. “It’s been a very reliable system for us. We’ve had great long-term success (…) I would highly recommend the SpeechMike Premium to any hospital with demanding dictation needs” explains Dave Baumgardner, Director of Information Management, Union Hospital in Dover, Ohio, USA.
Philips SpeechMike: A history of innovation
Speech Processing Solutions celebrated their 60th anniversary last year, driven by setting standards in the dictation industry by successful innovations. The original Philips SpeechMike was first launched in 1996. “The current top model, Philips SpeechMike Premium, is the result of almost two decades of attention to detail and striving for excellence through listening to customer’s needs from all over the world” explains Dr. Thomas Brauner, CEO of Speech Processing Solutions.
Made for speech recognition
Thanks to its special features such as the free floating microphone, the polished surface for non-sensitivity to touch noise, or the unique audio-optimized microphone grill, the Philips SpeechMike creates studio-like audio recordings . Together they successfully reduce unwanted surround sounds which enables two radiologists for example, to dictate simultaneously in one room without any interference. The clear recording levels enable the highest possible speech recognition accuracy. The dictation device is designed to work in perfect harmony with speech recognition software and has been awarded the highest possible Nuance speech recognition rating. This underlines Philips' position as global leader in audio competence, also underpinned by superior customer reviews.
Unlike many competitor products, the Philips SpeechMike offers exceptional features such as its antimicrobial housing, which is especially important in medical settings. The device fits perfectly into the hand where the ergonomic keyboard layout guarantees comfortable operation, even when dictating for several hours. Philips also carries out most extensive ‘stress tests’, making sure all devices are of exceptional quality, setting the benchmark in the dictation microphone industry. Dr. Thomas Brauner makes the point: “As our customers say: The best or nothing!”
For more information on the Philips SpeechMike please visit: www.philips.com/dictation
About Speech Processing Solutions
Speech Processing Solutions is the global number one in professional dictation. Founded in Austria in 1954 as part of Philips, the company has been the driving force in speech-to-text innovations for over 60 years. Always striving for excellence and putting emphasis on outstanding quality, the company has designed groundbreaking products, such as the portable Philips Pocket Memo voice recorder , the Philips SpeechMike Premium dictation microphone and the Philips SpeechExec dictation recorder app for smartphones. The latest innovation, Philips SpeechLive , makes dictation quicker and more convenient than ever before, by bringing secure dictation workflow to the cloud and enabling seamless speech-to-text with the new service Philips SpeechScribe. With solutions perfectly tailored to individual industry needs, Speech Processing Solutions has helped millions of satisfied customers around the globe save time and resources, allowing them to work as efficiently as possible.
Connect with Speech Processing Solutions on:
Facebook: http://www.facebook.com/philipsvoicetracer
Twitter @speech_com: http://www.twitter.com/speech_com
YouTube: http://www.youtube.com/philipsdictation
LinkedIn: http://www.linkedin.com/company/speech-processing-solutions
View source version on businesswire.com: http://www.businesswire.com/news/home/20151118005582/en/
./ContentItem/FormatPhilips SpeechMike Premium - the best or nothing
Contact:
Speech Processing Solutions
Richard Bancej
Richard.bancej@speech.com
Tel:
+43 1 60101-4191
www.philips.com/dictation
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
